The future of noncommercial research in EU member states is threatened by a new EU directive

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1435, 2004-01, pp. : 3-3

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

EU healthcare directive a new frontier for the UK?

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 558, 2008-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Challenges of the EU 'tissues and cells' directive

By Hartshorne Geraldine M  

Reproductive BioMedicine Online, Vol. 11, Iss. 4, 2005-10 ,pp. : 404-407

Reproductive Healthcare Ltd

Access to resources Recommend Favorite

Relative efficacy and effectiveness assessment of new pharmaceuticals in three EU member states: current practices and outcome agreement between Belgium, the Netherlands and France

By Wilder P.   Bormans V.   Dupont A.  

European Journal of Clinical Pharmacology, Vol. 69, Iss. 12, 2013-12 ,pp. : 2037-2043

Springer Publishing Company

Access to resources Recommend Favorite

EU Directive on clinical trials may be problematic

By  

Inpharma, Vol. 1, Iss. 1339, 2002-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Future EU strategy on health services

By Fahy Nick  

Clinical Medicine, Vol. 7, Iss. 1, 2007-01 ,pp. : 16-18

Royal College Of Physicians

Access to resources Recommend Favorite